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Hypoxia Modulates the Phenotype of Osteoblasts Isolated
From Knee Osteoarthritis Patients, Leading to
Undermineralized Bone Nodule Formation
Joan Chang,1 Sonya G. Jackson,2 John Wardale,3 and Simon W. Jones4
Objective. To investigate the role of hypoxia in the
pathology of osteoarthritic (OA) bone by exploring its
effect on the phenotype of isolated primary osteoblasts
from patients with knee OA.
Methods. OA bone samples were collected at the
time of elective joint replacement surgery for knee or
hip OA. Normal bone samples were collected postmor-
tem from cadaver donors. Primary osteoblasts were
isolated from knee OA bone chips and cultured under
normoxic or hypoxic (2% O2) conditions. Alkaline phos-
phatase activity was quantified using an enzymatic
assay, and osteopontin and prostaglandin E2 (PGE2)
production was assayed by enzyme-linked immunosor-
bent assay. Total RNA was extracted from bone
and osteoblasts, and gene expression was profiled by
quantitative reverse transcription–polymerase chain
reaction.
Results. Human OA bone tissue sections stained
positively for carbonic anhydrase IX, a biomarker of
hypoxia, and exhibited differential expression of genes
that mediate the vasculature and blood coagulation as
compared to those found in normal bone. Culture of
primary osteoblasts isolated from knee OA bone under
hypoxic conditions profoundly affected the osteoblast
phenotype, including the expression of genes that me-
diate bone matrix, bone remodeling, and bone vascula-
ture. Hypoxia also increased the expression of cyclo-
oxygenase 2 and the production of PGE2 by OA
osteoblasts. Osteoblast expression of type II collagen 1
chain, angiopoietin-like 4, and insulin-like growth factor
binding protein 1 was shown to be mediated by hypoxia-
inducible factor 1. Chronic hypoxia reduced osteoblast-
mineralized bone nodule formation.
Conclusion. These findings demonstrate that hyp-
oxia can induce pathologic changes in osteoblast func-
tionality consistent with an OA phenotype, providing
evidence that hypoxia is a key driver of OA pathology.
Although osteoarthritis (OA) has historically
been considered a disease of the cartilage, recent evi-
dence from animal models and clinical studies suggest
that pathologic remodeling of the subchondral bone
(1–5) precedes and mediates the changes observed in the
cartilage (5–11). Therefore, understanding the key mo-
lecular pathways that mediate pathologic bone remod-
eling in OA is critical in attempting to identify targets for
the development of new therapeutics that can modify
disease progression.
Importantly, knee and hip OA are both associ-
ated with vascular-related comorbidities (12–16), sug-
gesting a role of dysfunctional vasculature in OA pathol-
ogy. It is known that disruption of the vascular supply
and accompanying hypoxia are associated with modu-
lated bone formation during development and fracture
repair (17), and there is now evidence that vascular
dysfunction may also play a role in mediating subchon-
dral bone remodeling in OA (13,18).
Subchondral regions of the long bones are highly
vascularized and likely provide important nutrition to
the growth plate and articular cartilage, suggesting that
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compromised bone vasculature could affect both bone
and cartilage health. The subchondral bone in hip and
knee OA exhibits evidence of vascular dysfunction, with
vascular occlusion and reduced venous outflow (19,20),
which may result in local hypoxia (21). Furthermore,
bone ischemia has been linked to bone marrow lesions,
which are one of the morphologic hallmarks of OA bone
and are strong predictors of progressive cartilage degen-
eration and pain. Recent analysis of bone marrow
lesions from patients with knee OA showed that these
lesions consisted of highly undermineralized sclerotic
bone, with histopathologic features of secondary mod-
eling of vessels, evidence of fibrosis, and multiple throm-
bus inclusions, consistent with a localized oxygen deficit
(18). Therefore, a hypoxic microenvironment could be
responsible for driving sclerotic bone formation in OA.
Few studies have reported the role of hypoxia in
mediating OA bone pathology. Studies in osteoblast
cells lines and in murine osteoblasts suggest that hypoxia
can mediate osteoblast activity (22,23), but to our knowl-
edge, the effect of hypoxia on primary osteoblasts iso-
lated from patients with OA has not been reported. As
such, this potentially key driver of OA bone pathology is
currently poorly understood.
In this study, we first examined subchondral bone
obtained from patients with knee and hip OA for
evidence of biomarkers of hypoxia and the expression of
genes that mediate vasculature and blood coagulation.
We then isolated primary osteoblasts from the tibial
plateaus of patients with knee OA and examined the
effect of hypoxia on osteoblast activity and osteoblast
phenotype by measuring the expression of genes impli-
cated in bone remodeling, osteoblast/osteoclast cou-
pling, inflammation, and bone vasculature. In addition,
we examined the effect of chronic hypoxia on the ability
of primary knee OA osteoblasts to form mineralized
bone nodules.
MATERIALS AND METHODS
Tissues. Human OA subchondral joint tissue was
obtained at the time of total knee and hip joint replacement
operations. Normal bone was obtained postmortem from
cadaver donors with no history of joint pain (King’s Mill
Hospital, Sutton-in-Ashfield, UK). Following surgical removal,
OA and normal tissues were left to “rest” for 24 hours in
Dulbecco’s modified Eagle’s medium (DMEM) prior to pro-
cessing. The cartilage was then cut away from the tibial
plateau, and the bone was snap-frozen in liquid nitrogen.
Processing times were recorded to ensure that comparisons
could be made. Tissue samples from cadaver donors that had
evidence of OA on histologic examination were excluded from
the study.
For immunohistochemical studies, preliminary experi-
ments were conducted to determine the effect of time delay on
the outcome of immunohistochemical analysis, ensuring that
samples were processed within an acceptable time frame.
Samples were fixed in 10% buffered formalin and decalcified
using an EDTA-based protocol. Tissues were dissected to pro-
duce samples containing cartilage with underlying subchondral
bone, and were then processed and embedded in paraffin wax.
Full ethical consent was obtained from all tissue do-
nors or their families.
Immunohistochemical staining of human OA bone
sections. Immunohistochemical staining for the hypoxia bio-
marker carbonic anhydrase IX (CAIX) was performed on
4-m–thick sections obtained from OA and normal control
tissues. Antigen retrieval was performed by incubation over-
night at 60°C in 0.2M boric acid. CAIX was detected by
incubation for 60 minutes at room temperature with 1 g/ml
of rabbit anti-human CAIX antibody (ab15086; Abcam).
Detection was achieved using a biotinylated swine anti-
rabbit antibody (E0353; Dako), and StreptABComplex
(K0377; Dako). Visualization was performed using 3,3-
diaminobenzidine (Dako) with hematoxylin counterstain. The
isotype control we used was human adsorbed rabbit IgG
(PRABP01; Serotec) diluted to the same concentration as the
primary antibody.
Gene expression analysis of bone and primary human
osteoblasts. TRIzol (Invitrogen) was used to extract total RNA
from the medial and lateral tibial plateaus of the knees of age-
and sex-matched OA and normal donors (n  10 per group).
RNA quality was assessed with an Agilent Bioanalyzer, and all
samples had RNA integrity numbers that were 8.0. Gene
expression analysis in 10 g of total RNA was performed using
microarray gene chips (Human Genome U133 Plus 2.0 Arrays;
Affymetrix). Arrays were hybridized for 16 hours at 45°C,
washed, and stained with biotinylated antistreptavidin anti-
bodies and with streptavidin–phycoerythrin (Life Technolo-
gies). Images of the resulting arrays were scanned, and quality
control was determined using the following criteria. All scaling
factors obtained from each sample were confirmed to fall
within 3-fold of each other to enable cross-chip comparisons.
The percentage of present calls was between 45% and 55%.
The 3:5 ratio of GAPDH and actin was 3, which confirmed
that a good length of labeled transcript was generated. All
spike-in hybrid controls were called as present.
All data that passed these quality control criteria were
then analyzed using a Robust Multiarray Average algorithm.
Principle components analysis was performed, which showed
good separation of OA and normal control RNA from both the
lateral and medial tibia plateau compartments (data available
upon request from the corresponding author). To identify
differentially expressed genes, analysis of variance (ANOVA)
was performed, and a false discovery rate (FDR) was calcu-
lated for the entire study. The differentially expressed genes
were ranked according to the FDR, and P values and fold-
changes were determined (data available upon request from
the corresponding author).
Total RNA was extracted from primary osteoblasts
using RNeasy columns (Qiagen), and gene expression in
osteoblasts was quantified by quantitative reverse transcription–
polymerase chain reaction (qRT-PCR) analysis, using Micro-
fluidic TaqMan (Applied Biosystems). Ct values were normal-
ized to 18S RNA, and the comparative Ct method (Ct) was
used for the relative quantification of gene expression.
Ingenuity Pathway Analysis (IPA). The Affymetrix
gene expression data were uploaded to the IPA application
(www.ingenuity.com), and a core functional analysis was per-
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formed to identify canonical pathways that were most signifi-
cantly associated with the differentially expressed genes (using
a cutoff of 1.5-fold differentiation and P  0.05). The
significance of the association of a given canonical pathway
and the differentially expressed gene targets was measured in
two ways. First, the ratio of the number of genes in the network
that mapped to the canonical pathway divided by the total
number of genes that mapped to the canonical pathway was
calculated. Second, Fisher’s exact test was used to calculate the
P value for the association between the genes in the network
and the canonical pathway. We then analyzed the overlay of
the differentially expressed genes identified by the Affymetrix
analysis with the specific gene networks.
Preparation of primary osteoblasts. To isolate primary
osteoblasts, cartilage was removed from the femoral condyles
and tibial plateaus obtained from the patients with knee OA.
The revealed trabecular bone was cut into small pieces mea-
suring 2 mm3 and washed in growth medium (DMEM supple-
mented with 10% fetal calf serum, 200 units/ml of penicillin,
100 g/ml of streptomycin, 2 mM L-glutamine, 1% nonessen-
tial amino acids [Invitrogen] and 2.5 g/ml of amphotericin,
2 mM -glycerophosphate, 50 g/ml of ascorbic acid, and
10 nM dexamethasone). Bone explants were cultured in 125-
cm2 cell culture flasks, and the medium was replaced every 3–4
days until cells migrated out of the explants. Confluency was
reached in 21 days, at which time the cells were used (passage
0) or were split and grown to confluence again (passage 1).
Isolated primary osteoblasts exhibited positive expression of
RUNX-2, expressed osteopontin protein and alkaline phos-
phatase activity, and were also capable of mineralization and
forming bone nodules when allowed to become highly confluent.
On passaging the osteoblasts, there was evidence of changing
phenotype, with a significant reduction in alkaline phosphatase
activity, loss of osteopontin protein expression, and loss of
RUNX2 expression at passage 1 (data not shown). Therefore,
in all experiments, primary osteoblasts were used without
additional passaging to avoid any potential phenotypic drift.
At the end of the culture period, osteoblasts in mono-
layer were scraped into culture medium and centrifuged. Cell
pellets were resuspended in either radioimmunoprecipitation
assay (RIPA) buffer (50 mM Tris HCI, 150 mM NaCl, 1 mM
EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1%
sodium dodecyl sulfate [SDS], protease, and phosphatase
inhibitor cocktails) for protein isolation or RLT buffer (Qia-
gen) for RNA isolation. Cell culture supernatants were also
collected. Samples were stored at 80°C prior to analysis.
To stimulate the effect of hypoxia on bone, osteoblasts
were cultured under 2% oxygen conditions and in precondi-
tioned hypoxic growth medium.
Alkaline phosphatase activity. Total protein was quan-
tified using the bicinchoninic acid protein assay reagent
(Pierce). Alkaline phosphatase activity was tested with a
biochemical assay involving the conversion of p-nitrophenyl
phosphate into p-nitrophenol. An aliquot of the cell suspen-
sion in RIPA buffer was assayed for alkaline phosphatase
activity using p-nitrophenyl phosphate solution (Sigma). En-
zyme activity was expressed as units per milligram of protein.
Mineralization of primary human osteoblasts. Osteo-
blast mineralization was assessed by alizarin red S staining
(Sigma) of cells grown on 24-well plates. Cells were fixed with
10% formalin and stained with 40 mM alizarin red S (pH 4.1).
To quantify the degree of staining in each of the cultures, the
cultures were destained for 10 minutes at room temperature in
100 mM cetylpyridinium chloride. Aliquots of each sample
were transferred in triplicate to a 96-well plate, and the
absorbance was measured at a wavelength of 570 nm.
Detection of hypoxia-inducible factor 1 (HIF-1)
protein. Following incubation at 2% O2, osteoblasts were
removed from the incubator and immediately lysed in RIPA
buffer containing a protease inhibitor cocktail. Whole cell
lysates were then separated by SDS–polyacrylamide gel electro-
Figure 1. Immunohistochemical detection of carbonic anhydrase IX
(CAIX) in osteoarthritic (OA) bone. Samples of human OA femoral
heads containing cartilage and underlying subchondral and trabecular
bone were stained for the presence of CAIX protein. CAIX was
detected in chondrocytes, osteoblasts, osteoclasts, and endothelial
cells, as well as within calcified cartilage matrix, in OA bone and was
associated with regions undergoing active remodeling. A, CAIX stain-
ing of an OA bone sample appears to be increased in regions
associated with active bone formation, as indicated by high numbers of
activated osteoblasts. B, CAIX staining of a normal bone sample was
limited to the periarticular connective tissue, where it was seen in the
medial layer, with some blood vessels. Staining was negative within the
subchondral region. IgG control also showed negative staining within
the subchondral region (results not shown). Bar  250 m. Color
figure can be viewed in the online issue, which is available at
http://onlinelibrary.wiley.com/doi/10.1002/art.38403/abstract.
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phoresis, blotted onto an enhanced chemiluminescence (ECL)
membrane (GE Healthcare), probed with an HIF-1 poly-
clonal antibody at 1:500 dilution (Cell Signaling Technology),
and visualized using ECL Plus detection (GE Healthcare).
Determination of osteopontin protein and prostaglan-
din E2 (PGE2) levels by enzyme-linked immunosorbent assay
(ELISA). Conditioned medium from cultured primary osteo-
blasts were assayed for PGE2 using a commercially available
ELISA kit (KGE004; R&D Systems) and following the man-
ufacturer’s instructions. For the determination of osteopontin
protein, we used an in-house–developed ELISA. Briefly, 384-
well high-binding polystyrene plates (Costar) were coated
with capture antibody (R&D Systems) in phosphate buffered
saline (PBS) and left overnight at 4°C. Following removal of
the coating antibody, the plates were washed 3 times with
wash buffer (PBS containing 0.05% polysorbate), and the wells
were blocked for 1–2 hours at room temperature with 100 l/
well of PBS containing 1% bovine serum albumin. The plates
were then washed as above, and 40 l of sample or standard
was added to each well. Biotinylated anti-osteopontin (20 l/
well; R&D Systems) was added immediately, and the plate
was left for 2 hours before being aspirated. The plate was then
washed before the addition of horseradish peroxidase sub-
strate (diluted 1:2,500 in PBS) for 1 hour. All plates were
developed with the addition of 40 l/well of 3,3,5,5-
tetramethylbenzidine (TMB) for 20 minutes at room temper-
ature in the dark. The reaction was stopped with the addition
of H2SO4 (2M), and the absorbance was read at 450 nm
(PheraStar plate reader).
Statistical analysis. All data are reported as the
mean  SEM. Comparisons were performed using ANOVA,
with post hoc tests (least significant difference) used to deter-
mine significance. P values less than 0.05 were considered
significant.
RESULTS
Elevated expression of a hypoxia biomarker in
OA bone and differential expression of genes that
mediate the vasculature and blood coagulation. Immu-
nohistochemical staining of femoral head bone tissue
sections for CAIX, a known biomarker of hypoxia,
showed positive staining in OA subchondral bone sec-
tions. CAIX was detected in chondrocytes, osteoblasts,
osteoclasts, and endothelial cells, as well as within
calcified cartilage matrix in OA bone (Figure 1A).
CAIX staining also appeared to be particularly pro-
nounced in regions associated with new bone formation,
as indicated by the high numbers of activated osteo-
blasts. Samples of normal femoral heads showed nega-
tive staining in the subchondral bone region, although
there was staining for CAIX within the medial layer of
some blood vessels in the periarticular connective tissue
(Figure 1B).
Analysis of gene expression in OA and normal
subchondral tibial plateau bone revealed evidence of
altered expression of several genes in OA bone that are
known mediators of the vasculature and of blood co-
agulation, with similar findings in tissues from both the
medial and lateral tibial plateaus (Table 1). The most
Table 1. Differential expression of genes that mediate the vasculature and blood coagulation in OA tibial plateaus*
Gene Gene symbol
Fold change
FunctionMTP LTP
Angiogenesis and vascular modulation
Adrenomedullin ADM 18.0 23.0 Vasodilation; functions through RAMP receptors
Angiopoietin-like 4 ANGPTL4 3.0 3.0 Proangiogenic; apoptosis survival factor for
vascular endothelial cells
Collagen triple-helix repeat–containing 1 CTHRC1 4.6 4.5 Vascular repair; induced by fibroblasts and
modulates TGF signaling
EGF-like repeats and discoidin I–like
domains 3
EDIL3 2.2 2.3 Proangiogenic; expressed by endothelial cells in
response to VEGF and proinflammatory
cytokines IL-1 and TNF
Osteoglycin OGN 2.7 3.2 Vascular repair; increased during vascular injury
Receptor (G protein–coupled) activity–
modifying protein 1
RAMP1 1.5 1.7 Vasodilation; interacts with adrenomedullin
Vascular endothelial growth factor A VEGFA 2.1 2.1 Proangiogenic; promotes endothelial cell growth
and migration
Coagulation
CD84 antigen (leukocyte antigen) CD84 3.1 3.1 Platelet aggregation; homophilic adhesion
molecule promotes thrombosis
Plasminogen activator inhibitor 1 SERPINE1 2.0 2.7 Procoagulant; inhibits plasmin activation and
promotes fibrinolysis
Tissue factor pathway inhibitor TFPI 3.6 4.4 Anticoagulant; inhibits tissue factor/factor VIIa
complex
* Fold change values are shown for genes with a significant (P  0.05) and 1.5-fold differential expression between samples of the medial tibial
plateau (MTP) and lateral tibial plateau (LTP) from 10 patients with osteoarthritis (OA) and 10 cadaver donors (normal controls). Positive values
represent greater expression in OA samples; negative values represent greater expression in normal samples. TGF  transforming growth factor
; EGF  epidermal growth factor; VEGF  vascular endothelial growth factor; IL-1  interleukin-1; TNF  tumor necrosis factor .
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pronounced change was in the expression of adreno-
medullin, a potent vasodilator, which was down-
regulated 18-fold and 23-fold in the medial and lateral
tibial plateaus of OA bone, respectively, as compared
to normal tissue. In addition, both VEGFA and
ANGPTL4, key genes that mediate angiogenesis, were
Figure 2. Pathway analysis of Affymetrix gene data. A, Core functional analysis using the Ingenuity Pathway Analysis (IPA) application. Shown are
the most significantly differentiated pathways in osteoarthritic (OA) versus normal medial tibial plateau bone (using a cutoff of 1.5-fold dif-
ferentiation and P  0.05). The significance of the association of a given canonical pathway and the differentially expressed gene targets was mea-
sured in 2 ways: by the ratio of the number of genes in the network that mapped to the canonical pathway divided by the total number of genes that
mapped to the canonical pathway (orange plot), and by using Fisher’s exact test to calculate a P value for the association between the genes in the
network and the canonical pathway (blue bars). Yellow vertical line indicates threshold of significance. RA rheumatoid arthritis. B and C, Overlay
analysis of the differentially expressed genes from the Affymetrix gene data with the coagulation and cardiovascular disease gene network (B) and
the hematologic gene network (C). Red symbols represent genes that were up-regulated in OA versus normal bone; green symbols represent genes
that were down-regulated in OA versus normal bone. Shaded symbols represent genes that were not differentially expressed between OA and normal
bone. Open symbols represent nodes that are not shown in the microarray dataset but are included in the network based on previously known
interactions. Different shapes represent different molecular classes. Solid lines represent direct interactions. Broken lines represent indirect
interactions. Arrows that circle up and over the symbols represent self-interaction. Open arrowheads represent translocation. Asterisks indicate that
the gene is represented in the microarray dataset by multiple identifers.
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also down-regulated in OA bone. There was also in-
creased expression of EDIL3 (2-fold), CTHRC1 (5-fold),
and osteoglycin (3-fold), genes that have previously been
associated with vascular injury and remodeling (24,25).
In addition, there was an 4-fold down-
regulation in the expression of the anticoagulant TFPI, a
2-fold down-regulation in the expression of SERPINE1,
and increased expression of CD84, which mediates
platelet aggregation. This suggests an altered balance
between coagulation and fibrinolysis in OA bone tissue.
To further understand these findings, we up-
loaded our medial tibial plateau Affymetrix gene expres-
sion data to the IPA application (www.ingenuity.com)
and performed a core functional analysis. The results of
the canonical pathway analysis showed that from the
library of canonical pathways, the most significant path-
way was “role of osteoblasts, osteoclasts, and chondro-
cytes in RA.” However, among the most significant
pathways were “atherosclerosis signaling,” “intrinsic
prothrombin activation pathway,” and “inhibition of
angiogenesis by TSP1” canonical pathways (Figure 2A).
In addition, the canonical pathway “role of macro-
phages, fibroblasts, and endothelial cells in arthritis”
scored very highly where there was a high number of
differentially expressed bone Affymetrix genes associ-
ated with endothelial cell signaling (data not shown).
We then performed an overlay analysis of our
differentially expressed bone Affymetrix genes with spe-
cific gene networks and found a strong overlay of
differentially expressed genes with both the “coagulation
and cardiovascular disease” gene network (Figure 2B)
and the “hematologic” gene network (Figure 2C).
Hypoxia-modulated expression of genes that me-
diate matrix integrity and bone remodeling and reduced
activity of alkaline phosphatase. Culturing primary knee
OA osteoblasts under conditions of hypoxia (2% O2)
stabilized the expression of HIF-1, which became de-
tectable within 4 hours (Figure 3A). After 24 hours,
hypoxia had a profound effect on several genes pur-
ported to play a key role in bone remodeling, matrix
integrity, and the bone vasculature (Table 2).
Hypoxia induced a significant 8.5-fold increase in
the expression of MMP9 and a 16.2-fold increase in the
expression of COL2A1, the gene that expresses the
1(II) chain of type II collagen. However, there was
no significant effect on the expression of other bone
matrix collagens (COL1A1, COL1A2, COL5A1,
COL5A2, and COL13A). Hypoxia-treated osteoblasts
also modulated the expression of key bone osteoblast
transcription factors, which mediate osteoblast differen-
tiation, with increased expression of GADD45B, but
decreased expression of DLX5 and the osteoblast-
specific transcription factor SP7 (osterix). In addition,
hypoxia induced moderate increases in the expression of
both RANKL and the decoy receptor OPG, which are
Figure 3. Hypoxia modulation of primary human osteoarthritic (OA)
osteoblast alkaline phosphatase activity and prostaglandin E2 (PGE2)
production. Primary human OA osteoblasts were cultured in a 24-well
plate under hypoxic conditions (2% O2). A, Expression of hypoxia-
inducible factor 1 (HIF-1) in OA osteoblasts. At 0, 1, 2, and 4 hours,
osteoblasts were lysed using radioimmunoprecipitation assay buffer,
and total cell lysates were immunoprobed with an anti–HIF-1
antibody. B, Alkaline phosphatase (alk phosp) activity in OA osteo-
blasts. At 14 and 21 days, cells were lysed, and the total protein and
alkaline phosphatase activity were determined in the lysates. Values
are the mean  SEM (n  6 samples per group). C, After 24 and 48
hours, supernatants were harvested and the levels of PGE2 determined
using a commercially available enzyme-linked immunosorbent assay.
  P  0.01 versus the corresponding normoxic condition.
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known mediators of osteoblast/osteoclast coupling.
There was also a reduction in the expression of ALPL in
osteoblasts cultured under conditions of hypoxia, and
this was reflected with reduced alkaline phosphatase
activity, as determined by enzymatic assay, following
culture of osteoblasts under conditions of chronic hyp-
oxia (Figure 3B).
We also observed a hypoxia-induced elevation in
the expression of several growth factor signaling compo-
nents, with increased expression of FGF1, FGF2, and
NGFB. Although hypoxia had no effect on the expres-
sion of IGF1 in osteoblasts, there was the suggestion that
the IGF1 pathway was modulated, with the increased
expression of the IGF1 binding proteins IGFBP1 and
IGFBP3.
Hypoxia-modulated inflammatory cytokine and
COX2 expression and induction of PGE2 production.
Hypoxia also modulated the expression of key inflam-
matory cytokines from osteoblasts, with a reduction in
the expression of IL6 and CXCL12, but a 9-fold increase
in IL1B expression. In addition, hypoxia led to a mod-
erate yet significant increase (2-fold) in the expression of
PTGS2 (COX2), suggesting activation of the arachi-
donic acid/COX2 pathway. Indeed, we observed ele-
vated secretion of PGE2 in the supernatants of hypoxia-
treated osteoblasts as compared to normoxia-treated
osteoblasts (Figure 3C).
Hypoxia-modulated expression of genes that me-
diate the vasculature. Given the evidence of elevated
biomarkers of hypoxia in OA bone, we also examined
whether hypoxia-stimulated primary OA osteoblasts
showed altered expression of genes implicated in medi-
ating the bone vasculature (Table 2). Importantly, we
observed that hypoxia increased the expression of sev-
eral genes known to be proangiogenic, namely, VEGFA
and ANGPTL4, as well as elevating the expression of
EDN1. In contrast, hypoxia significantly reduced the
expression of ANGPTL1 as compared to normoxic
conditions. Hypoxia also led to elevated expression of
blood coagulation factors, with increased expression of
the procoagulant SERPINE1 and increased expression
of the anticoagulant PLAT.
Table 2. Effect of hypoxia on the phenotype of primary human osteoblasts isolated from patients with knee OA*
Gene Gene symbol TaqMan assay ID
Fold change
(hypoxia vs. normoxia)
Matrix remodeling
Type II collagen 1 COL2A1 Hs00264051_m1 16.2
Matrix metalloprotease 9 MMP9 Hs00234579_m1 8.5
Osteoblast activity
ADAM metallopeptidase domain 8 ADAM8 Hs00174246_m1 21.4
Growth arrest and DNA damage–inducible  GADD45B Hs00169587_m1 2.4
TNF receptor superfamily member 11b (OPG) TNFRSF11B Hs00171068_m1 2.0
TNF ligand superfamily member 11 (RANKL) TNFSF11 Hs00243522_m1 2.1
Distal-less homeobox 5 DLX5 Hs00193291_m1 2.0
Osterix SP7 Hs00541729_m1 10.5
Alkaline phosphatase liver/bone/kidney ALPL Hs00758162_m1 1.6
Inflammation
G protein–coupled receptor 68 GPR68 Hs00268858_s1 3.3
Interleukin-1 IL1B Hs00174097_m1 9.4
Prostaglandin endoperoxide synthase 2 (COX2) PTGS2 Hs00153133_m1 2.0
Interleukin-6 IL6 Hs00174131_m1 2.2
Chemokine (CXC motif) ligand 12 CXCL12 Hs00171022_m1 1.8
Vasculature modulation
Endothelin 1 EDN1 Hs00174961_m1 2.5
Vascular endothelial growth factor A VEGFA Hs00900054_m1 2.5
Angiopoietin-like 4 ANGPTL4 Hs00211522_m1 4.2
Angiopoietin 1 ANGPT1 Hs00266645_m1 1.9
Antithrombin SERPINC1 Hs00166654_m1 3.2
Plasminogen activator inhibitor type 1 SERPINE1 Hs00167155_m1 5.3
Tissue plasminogen activator PLAT Hs00263492_m1 5.6
Growth factor signaling
Fibroblast growth factor 1 FGF1 Hs00265254_m1 2.7
Fibroblast growth factor 2 FGF2 Hs00266645_m1 2.2
Insulin-like growth factor binding protein 1 IGFBP1 Hs00236877_m1 4.2
Insulin-like growth factor binding protein 3 IGFBP3 Hs00181211_m1 2.8
Nerve growth factor  NGFB Hs00171458_m1 6.0
* Shown are genes with a significant (P  0.05) and 1.5-fold differential expression in primary human osteoblasts derived from 4 osteoarthritis
(OA) patients and cultured for 24 hours under conditions of hypoxia versus normoxia. TNF  tumor necrosis factor; OPG  osteoprotegerin;
COX2  cyclooxygenase 2.
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Figure 4. Hypoxia-inducible factor 1 (HIF-1)–mediated expression of osteoblast genes and effect of chronic hypoxia on bone nodule formation. Primary
osteoblasts were cultured in a 12-well plate (2 	 105 cells/well) under normoxic or hypoxic conditions and treated with either dimethyl-
oxalylglycine (DMOG; 1 mM), 2-methoxyestradiol (2-ME; 200 M), or DMSO (control) for 24 hours (n  3 samples per condition). A, Protein lysates
prepared with radioimmunoprecipitation assay buffer were immunoprobed for HIF-1 expression. B, Total RNA was extracted, and the expression of
COL2A1, IGFBP1, and ANGPTL4 was quantified by quantitative reverse transcription–polymerase chain reaction analysis and normalized to 18S RNA.
C, Confluent primary human OA osteoblasts were cultured for 14 or 21 days in 24-well plates under normoxic or hypoxic conditions. Bone nodules were
then stained with alizarin red S, and the resulting stain was removed from the cells and released into the supernatant, and quantified by measuring its
absorbance at 570 nm. Values in B and C are the mean  SEM of 3 replicate experiments (B) or 3 separate donors (C).   P  0.05 versus the
corresponding media alone control; 
  P  0.05 versus the corresponding normoxic condition. D, Osteoblast bone nodules were cultured for 21 days
under normoxic or hypoxic conditions and then stained with alizarin red S. Original magnification 	 20. Color figure can be viewed in the online issue,
which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.38403/abstract.
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Mediation of osteoblast phenotype by modula-
tion of HIF-1 levels. To examine whether pharmaco-
logic modulation of HIF-1 levels in osteoblasts could
mediate the expression of the hypoxia-regulated osteo-
blast genes we previously identified, osteoblasts were
cultured for 24 hours under hypoxic or normoxic condi-
tions, with or without dimethyloxalylglycine (DMOG; a
cell-permeable prolyl-4-hydroxylase inhibitor which sta-
bilizes HIF-1) or 2-methoxyestradiol (2-ME; which
down-regulates HIF-1). First, we were able to demon-
strate that, as expected, treatment of normoxic osteo-
blasts with DMOG (1 mM) stabilized HIF-1 expres-
sion, while conversely, treatment of hypoxic osteoblasts
with 2-ME (200 M) inhibited the induction of HIF-1
(Figure 4A). Then, we analyzed by qRT-PCR the effect
of HIF-1 modulation on the expression of osteoblast
hypoxia-regulated genes. The majority of the genes
previously shown to be differentially expressed under
hypoxic conditions were not significantly altered by
1.5-fold with either DMOG or 2-ME. However, the
expression levels of ANGPTL4, COL2A1, and IGFBP1
were all partially regulated by pharmacologic modula-
tion of HIF-1 using DMOG and 2-ME (Figure 4B).
Chronic hypoxia–inhibited osteoblast mineraliza-
tion and bone nodule formation. To examine the effect of
chronic hypoxia on bone nodule formation, we allowed
primary OA osteoblasts to remain in culture in 24-well
plates for 21 days, during which time they became highly
confluent and formed bone nodules. Alizarin red S staining
for mineralization (to enable visualization of bone nodules)
showed that over this 21-day time course, hypoxia reduced
the degree of mineralization as compared to that in osteo-
blasts cultured under normal oxygen conditions (Figures
4C and D).
DISCUSSION
In this study, we have provided important infor-
mation on the role of hypoxia in OA bone pathology.
This study is the first to show the effect of hypoxia on the
phenotype of primary osteoblasts isolated from patients
with knee OA. We also provide further evidence sug-
gesting that subchondral bone tissue in OA patients is
hypoxic by showing that subchondral bone tissue from
patients with hip OA exhibits increased staining of a
biomarker of hypoxia and that subchondral bone from
patients with knee OA exhibits differential expression of
genes associated with coagulation and vasculature path-
ways as compared to normal control tissue.
Hypoxia had a profound effect on both the
activity and phenotype of primary OA osteoblasts iso-
lated from patients with knee OA, which could play a
key role in the development of sclerotic subchondral
bone, a feature of OA. For example, hypoxia affected
the expression of several osteoblast transcription factors
that are known mediators of osteoblast differentiation,
inducing an up-regulation in GADD45B expression and
a down-regulation of both DLX5 and the osteoblast-
specific transcription factor SP7 (osterix), which is con-
sidered to be a master regulator of osteoblast differen-
tiation (26) and to be necessary for mineralization and
bone formation (27–30). In addition, hypoxia reduced
both the messenger RNA expression and protein activity
of ALP, biomarkers of proliferative osteoblast activity.
Since it is known that a critical mass of differen-
tiated osteoblasts is required for the formation of ma-
ture mineralized bone, we believe it is likely that both
the hypoxia-induced down-regulation of the osteoblast-
specific transcription factor SP7, together with a reduc-
tion in osteoblast proliferative activity played a role in
the reduced mineralized bone nodule formation we
observed in osteoblasts following treatment under con-
ditions of chronic hypoxia, as compared to osteoblasts
cultured under normoxic conditions.
These findings confirm in a human disease set-
ting the previous observations of the effect of hypoxia on
osteoblast proliferative activity and bone nodule forma-
tion using murine osteoblasts (22,23). Importantly, sub-
chondral bone from OA patients is reported to be
undermineralized (31) and may contribute to the sub-
chondral bone sclerosis observed. As such, our finding
that hypoxia reduces osteoblast mineralized bone nodule
formation suggests that the hypomineralized OA bone
could be driven by vascular remodeling and local
hypoxia.
The formation of sclerotic subchondral bone in
OA (1,2) has also been linked to alterations in growth
factor signaling, particularly insulin-like growth factor 1
(32–35), as well as the urokinase plasminogen activator/
plasminogen system (32,34), both of which may modu-
late the bone matrix. Of interest, we found that hypoxia-
treated osteoblasts expressed higher levels of both
PLAT and SERPINE1. Furthermore, although there
was no effect of hypoxia on IGF1 expression, the
expression of both IGFBP1 and IGFBP3 was elevated,
suggesting that there was modulation of IGF1 signaling.
Sclerotic OA bone has also been reported to contain
altered expression of type I collagen genes (COL1A1
and COL1A2), leading to the formation of an abnormal
type I collagen homotrimer (36). Furthermore, osteo-
blasts isolated from regions of sclerotic bone have been
reported to express greater levels of both COL1A1 and
COL1A2 compared to osteoblasts from nonsclerotic
regions (37). In the present study, however, we found no
effect of hypoxia on the osteoblast expression of type I
collagen genes, but instead, we found a profound in-
HYPOXIA AND OSTEOBLASTS IN OA 1797
crease in the expression of the type 2 collagen gene
COL2A1, which is normally expressed predominantly in
cartilage and at lower levels in bone tissue.
Our data also suggest that primary OA osteo-
blasts respond to hypoxia by elevating the expression of
COX2 and producing greater amounts of PGE2. Al-
though we did not examine whether hypoxia affected EP
receptor expression levels, it is known that osteoblasts
express all 4 EP receptors. PGE2 is considered a putative
mediator of OA pain, and COX2 inhibitors have been
shown to be analgesic in clinical studies. However, the
role of PGE2 in bone pathology is unclear. It was
previously reported that PGE2 levels increase during
bone remodeling following fracture injury (38), and
other investigators have shown that PGE2 can stimulate
osteoblast proliferation (39,40). Therefore, the hypoxia-
induced elevation in PGE2 we report here could be an
attempt by the osteoblasts to enhance proliferation rates.
Our data demonstrating that hypoxia modulates
the osteoblast expression of several genes involved in the
maintenance of the bone vasculature and endothelial
cell integrity is intriguing. Previous studies (19,20) have
demonstrated that OA bone exhibits signs of vascular
obstruction, with reduced venous outflow. Importantly,
evidence of neovascularization has been reported at the
osteochondral junction in the OA joint (41). It is not
established whether this neovascularization provides
functional blood vessels, but it could be connected to our
findings that OA subchondral bone shows signs of
hypoxia, with neovascularization being a physiologic
response to promote reoxygenation. In this context, the
hypoxia-induced osteoblast expression of known media-
tors of angiogenesis (e.g., VEGF, ANGPTL4, ANGPT1,
EDN1) may suggest that subchondral osteoblasts sense
and respond to hypoxic microenvironments by mediating
the local bone vasculature and may therefore play a
central role in the neovascularization pathology previ-
ously reported within the OA osteochondral junction.
We also demonstrated that HIF-1 levels in
primary OA osteoblasts can be modulated using the
pharmacologic reagents DMOG and 2-ME, and that this
translated into regulation of COL2A1, IGFBP1, and
ANGPTL4 expression. However, pharmacologic modu-
lation of HIF-1 levels did not lead to significant
changes in all of the genes that we had previously shown
were differentially expressed under hypoxic culture con-
ditions. This could suggest the importance of other
hypoxia-mediated factors, such as other HIF family
members, or it could suggest that the effect of hypoxia
on the expression of many of the genes was partly an
indirect effect. For example, hypoxia induced a 9-fold
increase in IL1B expression, and it has previously been
found that IL1B can operate synergistically with hypoxia
to elevate levels of VEGF in synovial fibroblasts (42)
and articular chondrocytes (43). Another possibility is
that multiple dosing of primary osteoblast cells with
DMOG and 2-ME was required over the 24-hour period
in order to achieve sufficient HIF-1modulation to fully
recapitulate the effect of hypoxia.
In summary, the findings of the present study
show that the subchondral bone tissue of patients with
OA exhibits signs of hypoxia and exhibits differential
expression of genes that are known mediators of the
vascular system as compared to normal bone obtained
postmortem. Furthermore, we have shown that hypoxia
can modulate the activity and phenotype of osteoblasts
isolated from the tibia plateau bone of patients with
knee OA, negatively affecting the degree of mineralized
bone formation and modulating the expression of genes
that mediate bone matrix integrity, bone remodeling,
and bone vasculature. This suggests that identifying
therapeutic approaches that can target local hypoxia
within the subchondral bone may translate into effective
disease modification by modulating osteoblast activity
and preventing the formation of sclerotic undermineral-
ized bone, which is a characteristic feature of OA.
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